These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 34302920)

  • 21. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
    Wang L; Dou M; Ma Q; Yao R; Liu J
    Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.
    Li W; Wang X; Zhang X; Aziz AUR; Wang D
    Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
    Zhuang X; Long EO
    Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NK cell based immunotherapy against oral squamous cell carcinoma.
    Zhang Y; Xie J; Wu H; Huang J; Zheng D; Wang S; Jia X; He Z; Gong Y; Ju L; Sun Q
    Front Immunol; 2024; 15():1440764. PubMed ID: 39192980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges.
    Wu J
    BioDrugs; 2024 Jul; 38(4):499-509. PubMed ID: 38700835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting TRIM29 As a Negative Regulator of CAR-NK Cell Effector Function to Improve Antitumor Efficacy of these Cells: A Perspective.
    Saleh Z; Noroozi M; Vakili ME; Kabelitz D; Nasrollahi H; Kalantar K
    Curr Mol Med; 2024; 24(4):399-403. PubMed ID: 37218209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current progress in cancer immunotherapy based on natural killer cells.
    Bagheri Y; Barati A; Aghebati-Maleki A; Aghebati-Maleki L; Yousefi M
    Cell Biol Int; 2021 Jan; 45(1):2-17. PubMed ID: 32910474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Killers 2.0: NK cell therapies at the forefront of cancer control.
    Hodgins JJ; Khan ST; Park MM; Auer RC; Ardolino M
    J Clin Invest; 2019 Sep; 129(9):3499-3510. PubMed ID: 31478911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reprogramming natural killer cells for cancer therapy.
    Wang K; Wang L; Wang Y; Xiao L; Wei J; Hu Y; Wang D; Huang H
    Mol Ther; 2024 Sep; 32(9):2835-2855. PubMed ID: 38273655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
    Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
    Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.